Key result
A dual-strain feline calicivirus vaccine stimulated broader cross-neutralization antibodies than a single-strain vaccine and significantly reduced clinical signs in cats challenged with VS-FCV.
Answers are grounded in this paper and cite their sources.
Dual-strain FCV vaccine elicits cross-neutralizing antibodies; leaves open clinical efficacy against VS-FCV pending trials.
Feline calicivirus (FCV) causes an array of clinical disease in cats. Traditionally this disease has been associated with respiratory disease, limping, or chronic stomatitis. Within the last 10 years, virulent systemic feline calicivirus (VS-FCV) has been recognized which causes additional clinical signs and has a higher fatality rate. A dual-strain FCV vaccine containing a strain of FCV associated with traditional respiratory disease and a VS-FCV strain stimulates serum cross-neutralization antibodies when tested against field strains from Europe and VS-FCV strains from USA. Following challenge with a homologous VS-FCV strain, vaccinated cats had significantly reduced clinical signs.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2009) studied Feline calicivirus (FCV). Dual-strain FCV vaccine vs. Single-strain vaccine was evaluated on Serum cross-neutralization antibodies and clinical signs following challenge. A dual-strain feline calicivirus vaccine stimulated broader cross-neutralization antibodies than a single-strain vaccine and significantly reduced clinical signs in cats challenged with VS-FCV.
Synapse has enriched 10 related papers. Consider them for comparative context: